Reinvestigating Old Pharmacophores: Are 4-Aminoquinolines and Tetraoxanes Potential Two-Stage Antimalarials?
作者:Natasa Terzić、Jelena Konstantinović、Mikloš Tot、Jovana Burojević、Olgica Djurković-Djaković、Jelena Srbljanović、Tijana Štajner、Tatjana Verbić、Mario Zlatović、Marta Machado、Inês S. Albuquerque、Miguel Prudêncio、Richard J. Sciotti、Stevan Pecic、Sarah D’Alessandro、Donatella Taramelli、Bogdan A. Šolaja
DOI:10.1021/acs.jmedchem.5b01374
日期:2016.1.14
The syntheses and antiplasmodial activities of various substituted aminoquinolines coupled to an adamantane carrier are described. The compounds exhibited pronounced in vitro and in vivo activity against Plasmodium berghei in the Thompson test. Tethering a fluorine atom to the aminoquinoline C(3) position afforded fluoroaminoquinolines that act as intrahepatocytic parasite inhibitors, with compound 25 having an IC50 = 0.31 mu M and reducing the liver load in mice by up to 92% at 80 mg/kg dose. Screening our peroxides as inhibitors of liver stage infection revealed that the tetraoxane pharmacophore itself is also an excellent liver stage P. berghei inhibitor (78: IC50 = 0.33 mu M). Up to 91% reduction of the parasite liver load in mice was achieved at 100 mg/kg. Examination of tetraoxane 78 against the transgenic 3D7 strain expressing luciferase under a gametocyte-specific promoter revealed its activity against stage IV-V Plasmodium falciparum gametocytes (IC50 = 1.16 +/- 0.37 mu M). To the best of our knowledge, compounds 25 and 78 are the first examples of either an 4-aminoquinoline or a tetraoxane liver stage inhibitors.
[EN] ACYCLIC 1,3-DIAMINES AND USES THEREFOR<br/>[FR] 1,3-DIAMINES ACYCLIQUES ET LEURS UTILISATIONS
申请人:SMITHKLINE BEECHAM CORP
公开号:WO2006029210A3
公开(公告)日:2006-05-04
Acyclic 1,3-Diamine And Uses Therefor
申请人:Casillas N. Linda
公开号:US20070259965A1
公开(公告)日:2007-11-08
This invention relates to novel compounds useful in the treatment of diseases associated with TRPV4 channel receptor. More specifically, this invention relates to certain substituted amino-azepines, according to Formula I
or pharmaceutically acceptable salts, hydrates, or solvates thereof, wherein:
R
1
is aryl optionally substituted with CN, NO
2
, halogen or H;
R
2
is H, C
1
-C
6
alkyl, C
3
-C
7
cycloalkyl, or C
3
-C
7
heterocycloalkyl;
R
3
is H, OH, O—C
1
-C
6
alkyl, SH, S—C
1
-C
6
alkyl, or F;
R
4
is H, C
1
-C
6
alkyl
R
5
is iso-butyl, cyclohexylmethyl, or cyclopentylmethyl; and
R
6
is aryl, heteroaryl.